Drug Trial Radar · NCT05971589
A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
5
Planned (sponsor's estimate)
Start
Aug 2023
Primary completion
Apr 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 2, 2023
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients. The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and Interleukin-2 therapy.
Conditions
- Solid Tumor
Interventions
LM103Biological
Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AE), Serious adverse event (SAE) and immune related adverse events (irAE)Time frame: through study completion, an average of 1 year estimate
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.